References
- LuiQHeMShiHEfficacy and safety of different doses of a slow-release corticosteroid implant for macular edema: meta-analysis of randomized controlled trialsDrug Des Devel Ther2015925272535
- HallJComment on: “Use of the Fluocinolone Acetonide Intravitreal Implant for the Treatment of Noninfectious Posterior Uveitis: 3-Year Results of a Randomized Clinical Trial in a Predominantly Asian Population”Ophthalmol Ther201541656625786593
- HallJLetter to the editor: dexamethasone intravitreal implant in the treatment of diabetic macular edemaClin Ophthalmol201592119212126604676
- medicinces.org.uk [homepage on the Internet]Summary of Product Characteristics for ILUVIEN 190 μg intravitreal implant in applicatorEMC2015 [updated November 9, 2015]. Available from: https://www.medicines.org.uk/emc/medicine/27636Accessed: March 19, 2016
- Alimera Sciences. [press release] Available from: http://investor.alimerasciences.com/releasedetail.cfm?ReleaseID=873291Accessed 26 February 2016
- CampochiaroPABrownDMPearsonASustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edemaOphthalmology2012119102125213222727177
- BoyerDSYoonYHBelfortRJrThree-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edemaOphthalmology2014121101904191424907062
References
- CampochiaroPABrownDMPearsonALong-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edemaOphthalmology20111184626635.e221459216
- LuiQHeMShiHEfficacy and safety of different doses of a slow-release corticosteroid implant for macular edema: meta-analysis of randomized controlled trialsDrug Des Devel Ther2015925272535
- CabreraMYehSAlbiniTASustained-release corticosteroid optionsJ Ophthalmol2014201416469225140246